Company profile
MaxiVAX company profile
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX-ONCO-1. MaxiVAX’ mission is to develop alternative solutions to “established cancer therapies” that are more effective, are personalized and enable the patient to fight his own disease. MaxiVAX’ first treatment, MVX-ONCO-1 has been classified as an Advanced Therapeutic Product by the European Medicines Agency. The resulting approval procedure is different than that of a traditional drug and should generally allow a faster development until market approval with fewer and less extensive clinical trials.
Business identity
- Website
- http://www.maxivax.ch/
- Phone number
- +41 22 552 26 13
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $0-$1M
- Founded
- 2005-01-01, Year
Headquarters
- Headquarters
- Hasle, Lucerne, Switzerland
- Postal code
- 1206
- Country code
- CH
- Continent
- Europe